The EGM is over, and it was revealed that no trials have reported anything of note. Ropren sales are many months away, leading some analysts to suggest that SLA is "dead money." I am generally more optimistic, but I can't see any positive catalysts on the horizon. Anyway, with the directors the only ones buying, there is really little possibility of rebalancing the portfolio. Holders have no choice but to be patient, and hope for greater liquidity.
SLA Price at posting:
0.0¢ Sentiment: Sell Disclosure: Not Held
